Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
LENZ Therapeutics, Inc. - Common Stock
(NQ:
LENZ
)
27.93
+0.97 (+3.60%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
116,749
Open
27.00
Bid (Size)
26.20 (4)
Ask (Size)
27.50 (9)
Prev. Close
26.96
Today's Range
26.12 - 28.58
52wk Range
14.42 - 31.00
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024
October 30, 2024
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
LENZ Therapeutics' Investigational Drug For Age-Related Blindness Aces Pivotal China Trial, Analyst Says Data Readout May Strengthen Position For Ex-U.S. Partnerships
October 28, 2024
LENZ Therapeutics and Corxel Pharmaceuticals announced Phase 3 data for LNZ100, showing significant presbyopia improvements, supporting potential FDA approval.
Via
Benzinga
Exposures
Product Safety
Performance
YTD
+72.41%
+72.41%
1 Month
+24.24%
+24.24%
3 Month
+25.36%
+25.36%
6 Month
+72.62%
+72.62%
1 Year
+72.41%
+72.41%
More News
Read More
Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
October 28, 2024
Via
Benzinga
CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100
October 27, 2024
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
Why LENZ Therapeutics Stock Hit A New 52-Week High Today
October 21, 2024
Via
Benzinga
Exposures
Product Safety
LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia
October 21, 2024
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
LENZ Therapeutics Announces Presentations at Upcoming Ophthalmology and Optometry Medical Conferences
September 30, 2024
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
LENZ Therapeutics to Participate in Upcoming Investor Conferences
August 27, 2024
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
LENZ Stock Earnings: LENZ Therapeutics Misses EPS for Q1 2024
August 26, 2024
Via
InvestorPlace
LENZ Therapeutics Reports Second Quarter 2024 Financial Results
August 14, 2024
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia
August 12, 2024
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
LENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
August 07, 2024
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
LENZ Therapeutics Announces $30 Million Investment from Ridgeback Capital
July 15, 2024
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
ICC Holdings, Diamond Offshore Drilling, CrowdStrike And Other Big Stocks Moving Higher On Monday
June 10, 2024
Via
Benzinga
LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024
June 10, 2024
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
Why Skye Bioscience Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
June 10, 2024
Via
Benzinga
LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference
May 30, 2024
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
May 08, 2024
From
LENZ Therapeutics, Inc.
Via
GlobeNewswire
LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024
May 01, 2024
From
Lenz Therapeutics, Inc.
Via
GlobeNewswire
Blindness-Focused LENZ Therapeutics' Investigational Eye Drop Ready To Revolutionize Presbyopia Landscape, Analyst Says
April 10, 2024
Via
Benzinga
Newly Listed Lenz Therapeutics' Vision Loss Experimental Drug Meets Primary Goal In Late-Stage Study
April 03, 2024
Via
Benzinga
LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials
April 03, 2024
From
LENZ Therapeutics, Inc.
Via
Business Wire
LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials
April 02, 2024
From
LENZ Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
March 29, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.